Despite substantial health benefits, two GLP-1 receptor agonists weren't cost-effective at their current prices, according to ...

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.

Customers can expect a rate hike up to 14 percent as employee welfare costs surge related to Ozempic and drugs like it.

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.